

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method, comprising:
identifying an infarct region within ~~the~~a ventricle of a human subject; and
percutaneously delivering a non-antigenic cell line comprising α -1,3-
galactosyltransferase (GGTA1) knock-out swine cells to the infarct region within the ventricle of
the human subject, wherein the knock-out swine cells do not express α -1,3-galactosyltransferase
(GGTA1) and wherein the knock-out swine cells stimulate a beneficial response within the
ventricle.
2. (Canceled)
3. (Currently Amended) The method of claim 1, wherein the donor cells are diploid and
both chromosomal copies of a gene for ~~α -1,3-galactosyltransferase (GGTA1) knock-out swine~~
~~cells~~of a donor cell have been disrupted.
4. (Canceled)
5. (Currently Amended) The method of claim 1, ~~further comprising delivering at least one~~
~~structurally reinforcing agent to the infarct region to increase the modulus of elasticity of~~
~~the~~wherein delivering comprises delivering an amount of donor cells to structurally reinforce
infarct region.
6. (Currently Amended) The method of claim 1, wherein the donor cells replace damaged
cells in and around the infarct region.
7. (Currently Amended) The method of claim 1, wherein delivery of the ~~non-antigenic cell~~
~~line~~donor cells occurs within 2 weeks of a myocardial infarction (MI).

8. (Currently Amended) The method of claim 1 wherein a nucleic acid encoding a detectable polypeptide carried by the ~~non-antigenic cell line~~donor cells is operably linked to a promoter.

9-18. (Canceled)

19. (Currently Amended) A method, comprising:
identifying an infarct region within a ventricle of a subject;
applying a pacing therapy to the ventricle to pre-excite the infarct region to ~~unload the infarct region from mechanical stress~~contract during systole at a time before contraction of the ventricle initiated by the His Purkinje conduction network; and
percutaneously delivering ~~an~~ at least one structurally reinforcing component to the infarct region after applying the pacing therapy.

20. (Currently Amended) The method of claim 19, wherein the at least one structurally reinforcing component comprises donor cells from a non-antigenic cell line of swine cells that do not express α -1,3-galactosyltransferase (GGTA1)~~knock-out swine cells~~.

21. (Previously Presented) The method of claim 19, wherein the pacing therapy comprises a bradycardia pacing algorithm.

22. (Currently Amended) The method of claim 19, further comprising modifying the pacing therapy based upon ~~sensor measurements~~a sensed measurement.

23-62 (Canceled)

63. (New) The method of claim 22, wherein the sensed measurement comprises wall motion during the cardiac cycle.

64. (New) The method of claim 22, wherein the sensed measurement comprises impedance signals from a paced region and a non-ischemic region.

65. (New) The method of claim 22, wherein the sensed measurement comprises a change in a wall thickness of a paced region.

66. (New) The method of claim 1, wherein the donor cells comprise stem cells.

67. (New) The method of claim 20, wherein the donor cells comprise stem cells.

68. (New) The method of claim 19, wherein the structurally reinforcing component has a property that stimulates a healing response in the ventricle.